{"product_id":"ifn-alphabeta-r1-his-tag-protein-human-ua011351","title":"IFN-alpha\/beta R1 His Tag Protein, Human","description":"\u003ch4\u003eProduct Specification\u003c\/h4\u003e\u003cdiv class=\"responsive-table product-detail-table details-table\"\u003e\n\u003cbr\u003e\u003ctable style=\"width: 100%; height: auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eIFNAR1,IFNAR,CRF2-1,IFN-R-1,IFNAR-1,IFNBR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eP17181-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eAmino Acid Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003eLys28-Lys436 with His Tag at the C-Terminus\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e70-95kDa (Reducing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e＞95% by SDS-PAGE \u0026amp; \u0026gt; 95% by SEC-HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConjugation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHis Tag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePhysical Appearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStorage Buffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003ePBS, PH7.4, 5% trehalose\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eReconstitute at 0.1-1 mg\/ml according to the size in ultrapure water after rapid centrifugation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStability \u0026amp; Storage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.\u003cbr\u003e· 3 months, -20 to -80℃ under sterile conditions after reconstitution.\u003cbr\u003e· 1 week, 2 to 8℃ under sterile conditions after reconstitution.\u003cbr\u003e· Please avoid repeated freeze-thaw cycles.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eReference\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e1.Groen K, Kuratli R, Enkelmann J, Fernbach S, Wendel-Garcia PD, Staiger WI, Lejeune M, Sauras-Colón E, Roche-Campo F, Filippidis P, Rauch A; Swiss HIV Cohort Study; Trkola A, Günthard HF, Kouyos RD, Brugger SD, Hale BG. Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design. J Exp Med. 2025 Jun 2;222(6):e20242039.\u003cbr\u003e2.Amendolara R, D'Onofrio L, Sessa RL, Di Giulio S, Mignogna C, Coraggio L, Schirano R, Zampetti S, Malandrucco I, Pozzilli P, Giannini G, Maddaloni E, Buzzetti R. IFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes. J Clin Endocrinol Metab.\u003cbr\u003e3.Abramovich C,et al.(1997) A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J. 16(2): 260-6.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003c\/div\u003e\u003ch4\u003eBackground\u003c\/h4\u003e\u003cdiv\u003e\u003cp\u003eInterferon α\/β receptor 1 (IFNAR1) is a key component of the type I interferon (IFN-α\/β) receptor. It belongs to the type II cytokine receptor family and is a type I transmembrane protein. Its extracellular region contains four fibronectin type III domains. IFNAR1 must form a functional receptor complex with another subunit, IFNAR2, to mediate type I interferon signal transduction. Upon ligand binding, the receptor activates downstream JAK kinases (such as Tyk2), which in turn phosphorylate transcription factors such as STAT1 and STAT2, initiating the expression of antiviral and immunomodulatory genes. Research suggests that its signaling mechanisms are complex: on the one hand, under specific conditions (such as during IFN-β signaling), IFNAR1 can function independently without relying on IFNAR2, and this pathway may not involve the classical JAK-STAT pathway; on the other hand, Tyk2 can stabilize IFNAR1 expression by inhibiting its endocytosis, while mutations at key tyrosine sites (e.g., Tyr466) can block STAT phosphorylation in a dominant-negative manner, confirming the central role of IFNAR1 in linking JAK and STAT. IFNAR1 itself also possesses direct antiviral activity.As the gateway for type I interferon signaling, IFNAR1 is a critical target in antiviral immunity, autoimmune diseases, and tumor immunotherapy. Hyperactivation or abnormal signaling of the receptor is associated with autoimmune diseases (such as systemic lupus erythematosus), while functional defects may increase susceptibility to viral infections. Modulation of this receptor and its signaling pathway provides important directions for the development of antiviral drugs, therapies for autoimmune diseases, and novel immune adjuvants.\u003c\/p\u003e\u003c\/div\u003e","brand":"UA BIOSCIENCE","offers":[{"title":"25μg","offer_id":42332761522251,"sku":null,"price":185.0,"currency_code":"USD","in_stock":true},{"title":"100μg","offer_id":42332761555019,"sku":null,"price":380.0,"currency_code":"USD","in_stock":true},{"title":"500μg","offer_id":42332761587787,"sku":null,"price":1165.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":42332761620555,"sku":null,"price":1850.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/8375\/1499\/files\/AntBioImage_66c6b27c-99a9-44e7-b48f-5b9e844fed87.png?v=1776073551","url":"https:\/\/www.antbioinc.com\/products\/ifn-alphabeta-r1-his-tag-protein-human-ua011351","provider":"AntBio","version":"1.0","type":"link"}